A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
NCT ID: NCT02598440
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
341 participants
INTERVENTIONAL
2004-03-31
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: Ibandronate Then Alendronate
Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
Alendronate
Participants wil receive once-weekly oral alendronate (70 mg tablet)
Ibandronate
Participants wil receive once-monthly oral ibandronate (150 mg tablet)
Group B: Alendronate Then Ibandronate
Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
Alendronate
Participants wil receive once-weekly oral alendronate (70 mg tablet)
Ibandronate
Participants wil receive once-monthly oral ibandronate (150 mg tablet)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alendronate
Participants wil receive once-weekly oral alendronate (70 mg tablet)
Ibandronate
Participants wil receive once-monthly oral ibandronate (150 mg tablet)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of post-menopausal osteoporosis
* Women who have never received bisphosphonate therapy, or who have discontinued daily bisphosphonates at least 3 months prior to study entry
Exclusion Criteria
* Allergy to bisphosphonates;
* Previous or current treatment with weekly or monthly bisphosphonates, or daily bisphosphonates for the last 3 months prior to study entry
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_CHAIR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntsville, Alabama, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
Laguna Woods, California, United States
Mission Viejo, California, United States
Oceanside, California, United States
San Diego, California, United States
San Diego, California, United States
Santa Clarita, California, United States
Upland, California, United States
Vista, California, United States
Denver, Colorado, United States
Cromwell, Connecticut, United States
Waterbury, Connecticut, United States
Newark, Delaware, United States
Aventura, Florida, United States
Miami, Florida, United States
Pembroke Pines, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Augusta, Georgia, United States
Decatur, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
South Bend, Indiana, United States
Des Moines, Iowa, United States
Wichita, Kansas, United States
Bangor, Maine, United States
Baltimore, Maryland, United States
Worcester, Massachusetts, United States
Florissant, Missouri, United States
St Louis, Missouri, United States
Reno, Nevada, United States
Princeton, New Jersey, United States
Toms River, New Jersey, United States
Orchard Park, New York, United States
Raleigh, North Carolina, United States
Eugene, Oregon, United States
Duncansville, Pennsylvania, United States
Erie, Pennsylvania, United States
Erie, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Wyomissing, Pennsylvania, United States
Warwick, Rhode Island, United States
Mt. Pleasant, South Carolina, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Newport News, Virginia, United States
Richmond, Virginia, United States
Seattle, Washington, United States
Seattle, Washington, United States
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA17843
Identifier Type: -
Identifier Source: org_study_id